ZUBRELGA
Live / Registered — Registered (as of 10 Mar 2026)
What this means for you
Registered since 10 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98093675
- Registration number
- 8164334
- Mark type
- Stylized text
- Filed
- 20 Jul 2023
- Published for opposition
- 07 May 2024
- Registered
- 10 Mar 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 10 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Feb 2026 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 04 Jul 2025 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 27 Jun 2025 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 12 Nov 2024 — NOTICE OF ALLOWANCE CANCELLED
- 27 Jun 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Nov 2024 — TEAS DELETE 1(B) BASIS RECEIVED
- 02 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 May 2024 — PUBLISHED FOR OPPOSITION
- 17 Apr 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Apr 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER